Prospective evaluation of moxalactam therapy for gram-negative bacillary meningitis.
In a prospective evaluation twenty patients with gram-negative bacillary meningitis were treated with moxalactam, either alone or in conjunction with other antibiotics. Of thirteen patients who received only moxalactam, eight recovered, one failed to respond, and five died of causes other than meningitis. Cultures of CSF were negative before death in each instance. Thirteen (65%) of 20 treated patients recovered. Reversible hypoprothrombinemia and bleeding occurred secondary to moxalactam therapy in one patient. The mortality from gram-negative bacillary meningitis remains high owing to the incidence of associated underlying disease. Moxalactam brings about bacteriologic control in a large proportion of patients who are infected with highly sensitive gram-negative enteric bacilli.
D000151:Acinetobacter Infections / Q000150:complications / Q000188:drug therapy*; D000293:Adolescent; D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D004756:Enterobacteriaceae Infections / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008581:Meningitis / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged; D009070:Moxalactam / Q000009:adverse effects / Q000134:cerebrospinal fluid / Q000627:therapeutic use*; D011446:Prospective Studies; D011517:Prothrombin Time
D009070:Moxalactam